莫西沙星联合匹多莫德治疗老年呼吸道感染患者的效果及细胞免疫指标评估

Effect And Cellular Immune Indexes Evaluation Of Moxifloxacin Combined With Pidotimod In Treatment Of Elderly Patients With Respiratory Tract Infections

目的探析莫西沙星联合匹多莫德治疗老年呼吸道感染的临床效果以及对细胞免疫指标的影响。方法选择典型的老年呼吸道感染患者纳入研究,时间节点为2018年4月至2019年4月,例数共计94,将上述患者分为研究组、对照组,人数均分,对照组用匹多莫德治疗,研究组用莫西沙星联合匹多莫德治疗,对比分析两组的临床效果以及细胞免疫指标数据。结果研究组临床治疗效果明显较好,对细胞免疫指标的改善也有明显优势,差异有统计学意义,P<0.05。结论在老年呼吸道感染患者中采用莫西沙星联合匹多莫德进行治疗,可以优化疗效,对于细胞免疫指标的改善也有一定的作用和价值,可推广使用。

Objective To explore clinical effect and cellular immune indexes of moxifloxacin combined with pidotimod in treatment of elderly respiratory tract infections.Methods We chose 94 cases of typical elderly patients with respiratory tract infections from April 2018 to April 2019 in the study,divided them into study group and control group in average.Control group was treated with pidotimod,and study group with moxifloxacin combined with pidotimod treatment.Compared and analyzed clinical effect and cellular immune index data of two groups.Results Data analysis showed:clinical treatment effect of study group was significantly better,with obvious advantages in improving cellular immune indexes,difference was statistically significant,P<0.05.Conclusion Moxifloxacin combined with pidotimod can optimize curative effect in treatment of elderly patients with respiratory tract infections,with certain effect and value on improvement of cellular immune indexes,which can be widely applied.